Lacosamide Hikma Farmacêutica

Lacosamide, the active ingredient in Lacosamide Hikma Farmacêutica, is an anti-epileptic drug presented as an intravenous solution for intravenous use. It is used as adjunctive therapy for partial‑onset seizures and primary generalized tonic‑clonic seizures in patients who require additional seizure control.

GNH USA supplies Lacosamide Hikma Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacy networks worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Lacosamide is an anticonvulsant indicated for the treatment of epilepsy, specifically targeting seizure types that arise from abnormal neuronal firing. - Partial‑onset seizures: used as adjunctive therapy to reduce seizure frequency in patients with focal epilepsy. - Primary generalized tonic‑clonic seizures: added to existing regimens to improve control of generalized seizures. - Status epilepticus (intravenous use): may be employed in acute settings when rapid seizure control is required.

Lacosamide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: generalized tiredness. - Vision changes: blurred or double vision. - Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmias: including PR‑interval prolongation. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Respiratory depression: reduced breathing effort. - Hypotension: significant drop in blood pressure.

When prescribing Lacosamide, clinicians should consider several safety and handling precautions. - Renal impairment: adjust monitoring as the drug is renally excreted. - Cardiac conduction disorders: evaluate ECG for PR‑interval changes. - Concomitant CNS depressants: monitor for enhanced sedation. - Pregnancy: use only if potential benefit justifies potential risk, as data are limited. - Elderly patients: start at lower doses and observe for tolerance. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide plasma levels. - Concomitant use with other sodium‑channel blockers (e.g., carbamazepine, oxcarbazepine): increased risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Opioids or benzodiazepines: additive CNS depression. - Alcohol: enhances sedative effects. - Contraceptive hormones: possible reduction in efficacy.